AstraZeneca said the combination of its experimental drug CeralaSertiB and imfinzi, an approved cancer treatment drug, failed to meet the main goals in a late-stage clinical trial for advanced lung cancer. The British pharmaceutical company said on Monday that the results of the study showed that compared to standard treatments for patients with locally advanced or metastatic non-small cell lung cancer, the ceralasertib combination failed to meet the main goal of overall survival. AstraZeneca said the combination of CeralaSertib and imfinzi was generally well tolerated and no new safety concerns emerged.

AstraZeneca said the combination of its experimental drug CeralaSertiB and imfinzi, an approved cancer treatment drug, failed to meet the main goals in a late-stage clinical trial for advanced lung cancer. The British pharmaceutical company said on Monday that the results of the study showed that compared to standard treatments for patients with locally advanced or metastatic non-small cell lung cancer, the ceralasertib combination failed to meet the main goal of overall survival. AstraZeneca said the combination of CeralaSertib and imfinzi was generally well tolerated and no new safety concerns emerged.